echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Leukemia: Comprehensive clinical evaluation of Guadecitabine (SGI-110) in peripheral T-cell lymphoma

    Leukemia: Comprehensive clinical evaluation of Guadecitabine (SGI-110) in peripheral T-cell lymphoma

    • Last Update: 2022-05-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Peripheral T-cell lymphoma (PTCL) is a rare, heterogeneous malignancy that relapses with poor patient outcomes


    Peripheral T-cell lymphoma (PTCL) is a rare, heterogeneous malignancy that relapses with poor patient outcomes


    Hypomethylating agents (HMAs) are a class of epigenetic antineoplastic drugs that have been previously shown to have a role in PTCL, along with genetic mutations shared with myelodysplastic syndromes (MDS)





    In this phase II, single-arm trial, patients with PTCL received guadecitabine on days 1-5 of a 28-day treatment cycle


    In this phase II, single-arm trial, patients with PTCL received guadecitabine on days 1-5 of a 28-day treatment cycle







    Wong, J.


    https://doi.
    org/10.
    1038/s41375-022-01571-8

    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.